Long-term safety and efficacy of tralokinumab in patients with moderate-to-severe atopic dermatitis treated for up to 6 years: final results from the open-label extension trial ECZTEND / Andrew Blauvelt, H. Chih-Ho Hong, Norito Katoh, Richard G. Langley, Vivian Laquer, Aleksandra Lesiak, Ketty Peris, Julien Seneschal, Juan-Francisco Silvestre, Richard B. Warren, Andreas Wollenberg, Matthew Zirwas, Niels Højsager Bennike, Farzaneh Safavimanesh, Ann-Marie Tindberg, Kristian Reich

Related documents

• Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND#144942
• Efficacy and Safety of a Topical Botanical Extract Formulation for Skin Aging#1088337
• DIETARY FACTORS AND THEIR INFLUENCES ON ATOPIC DERMATITIS: INTEGRATING CROSS–SECTIONAL, LONGITUDINAL, AND RANDOMIZED CONTROLLED TRIAL APPROACHES#190571
• DIETARY FACTORS AND THEIR INFLUENCES ON ATOPIC DERMATITIS: INTEGRATING CROSS–SECTIONAL, LONGITUDINAL, AND RANDOMIZED CONTROLLED TRIAL APPROACHES#190101
• To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa#912921